DDInter458 DDInter1959
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) binds {v} (Gene) ABCC1
ABCC1 {u} (Gene) is bound by {v} (Compound) Ibuprofen
Ibuprofen {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) PAN2
PAN2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) TP53
TP53 {u} (Gene) is bound by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Cyclosporine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Cyclosporine (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Ibuprofen (Compound) and Ibuprofen may lead to a major life threatening interaction when taken with Zanubrutinib
Cyclosporine (Compound) upregulates PAN2 (Gene) and PAN2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Zanubrutinib
Cyclosporine (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Zanubrutinib
Cyclosporine (Compound) upregulates TP53 (Gene) and TP53 (Gene) is bound by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Zanubrutinib
Cyclosporine (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Cyclosporine (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Cyclosporine (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Cyclosporine (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Zanubrutinib